Fig. 7From: In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line2D and 3D binding mode of compound 16 in the binding site of the EGFR receptorBack to article page